Letrozole Bluefish

Letrozole, the active ingredient in Letrozole Bluefish, is an aromatase inhibitor presented as an oral tablet for oral use. It is indicated for hormone receptor‑positive breast cancer in postmenopausal women, where it reduces estrogen synthesis to help control tumor growth.

GNH USA supplies Letrozole Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is used in the management of estrogen‑dependent breast cancer, acting on the hormonal pathway that drives tumor growth.

- Adjuvant treatment of early‑stage hormone receptor‑positive breast cancer: helps prevent disease recurrence. - Metastatic hormone receptor‑positive breast cancer: slows disease progression in advanced disease. - Postmenopausal women with estrogen‑dependent breast cancer: reduces estrogen production to inhibit tumor growth.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching discomfort in limbs. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain in the head. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Severe liver injury: jaundice, dark urine, abdominal pain. - Bone fractures: increased risk due to reduced bone mineral density. - Pulmonary embolism: sudden shortness of breath, chest pain. - Severe allergic reactions: rash, swelling, difficulty breathing. - QT interval prolongation: irregular heart rhythm that may cause fainting.

When prescribing Letrozole, clinicians should consider several safety measures.

- Pregnancy contraindication: drug is category X and may cause fetal harm; avoid use in pregnant women. - Menopausal status: indicated only for postmenopausal patients. - Bone health monitoring: assess bone mineral density regularly due to risk of osteoporosis. - Liver function monitoring: check hepatic enzymes before and during therapy. - Drug interaction vigilance: avoid concomitant estrogen‑containing products. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Letrozole can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Estrogen‑containing hormone therapy: may counteract Letrozole’s effect. - Strong CYP2A6 inhibitors (e.g., fluvoxamine): can increase Letrozole plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce Letrozole exposure. - Anticoagulants (e.g., warfarin): monitor INR as Letrozole may affect metabolism. - Thyroid hormone replacement: adjust dose if thyroid function changes.